Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
CRNX Crinetics Pharmaceuticals Inc
- Stocks
- Healthcare
- NASDAQ: CRNX
Price (delayed)
$32.7
Market cap
$3.04B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$3.69
Enterprise value
$2.83B
Crinetics Pharmaceuticals is a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate,
Highlights
CRNX's equity has surged by 146% year-on-year and by 59% since the previous quarter
The quick ratio has soared by 79% YoY and by 41% QoQ
The revenue has dropped by 74% year-on-year
CRNX's gross profit has plunged by 74% YoY
Key stats
What are the main financial stats of CRNX
Market
Valuations
Earnings
Shares outstanding
93.05M
Market cap
$3.04B
Enterprise value
$2.83B
Price to earnings (P/E)
N/A
Price to book (P/B)
2.29
Price to sales (P/S)
2,542.45
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2,723.16
Revenue
$1.04M
Gross profit
$1.04M
Operating income
-$338.85M
Net income
-$298.41M
EBIT
-$298.41M
EBITDA
-$292.58M
Free cash flow
-$229.81M
Per share
Balance sheet
Liquidity
EPS
-$3.69
EPS diluted
-$3.69
Free cash flow per share
-$2.84
Book value per share
$14.29
Revenue per share
$0.01
TBVPS
$17.76
Total assets
$1.43B
Total liabilities
$109.79M
Debt
$51.72M
Equity
$1.32B
Working capital
$1.32B
Debt to equity
0.04
Current ratio
23.04
Quick ratio
22.7
Net debt/EBITDA
0.73
Margins
Efficiency
Dividend
EBITDA margin
-28,159.9%
Gross margin
100%
Net margin
-28,720.7%
Operating margin
-32,613.5%
Return on assets
-27.9%
Return on equity
-30.9%
Return on invested capital
-39.9%
Return on capital employed
-21.7%
Return on sales
-28,720.7%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
CRNX stock price
How has the Crinetics Pharmaceuticals stock price performed over time
Intraday
4.17%
1 week
-2.45%
1 month
27.93%
1 year
-35.74%
YTD
-36.05%
QTD
-2.5%
Financial performance
How have Crinetics Pharmaceuticals's revenue and profit performed over time
Revenue
$1.04M
Gross profit
$1.04M
Operating income
-$338.85M
Net income
-$298.41M
Gross margin
100%
Net margin
-28,720.7%
The revenue has dropped by 74% year-on-year
CRNX's gross profit has plunged by 74% YoY
CRNX's operating income has plunged by 52% YoY and by 10% from the previous quarter
CRNX's net income is down by 39% year-on-year and by 7% since the previous quarter
Price vs fundamentals
How does CRNX's price correlate with its fundamentals
Growth
What is Crinetics Pharmaceuticals's growth rate over time
Valuation
What is Crinetics Pharmaceuticals stock price valuation
P/E
N/A
P/B
2.29
P/S
2,542.45
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2,723.16
CRNX's equity has surged by 146% year-on-year and by 59% since the previous quarter
CRNX's P/B is 44% below its last 4 quarters average of 4.1 and 35% below its 5-year quarterly average of 3.5
The revenue has dropped by 74% year-on-year
The P/S is 74% above the 5-year quarterly average of 1457.5 but 17% below the last 4 quarters average of 3045.9
Efficiency
How efficient is Crinetics Pharmaceuticals business performance
The company's return on equity rose by 42% YoY and by 14% QoQ
The ROA has increased by 39% YoY and by 13% from the previous quarter
The return on invested capital rose by 27% year-on-year and by 13% since the previous quarter
The company's return on sales fell by 7% QoQ
Dividends
What is CRNX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for CRNX.
Financial health
How did Crinetics Pharmaceuticals financials performed over time
The total assets has surged by 126% year-on-year and by 53% since the previous quarter
The quick ratio has soared by 79% YoY and by 41% QoQ
The debt is 96% smaller than the equity
CRNX's equity has surged by 146% year-on-year and by 59% since the previous quarter
CRNX's debt to equity has dropped by 60% year-on-year and by 33% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.